Intrinsic value of Antares Pharma - ATRS

Previous Close

$2.25

  Intrinsic Value

$0.07

stock screener

  Rating & Target

str. sell

-97%

Previous close

$2.25

 
Intrinsic value

$0.07

 
Up/down potential

-97%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of ATRS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  13.04
  15.40
  14.36
  13.42
  12.58
  11.82
  11.14
  10.53
  9.97
  9.48
  9.03
  8.63
  8.26
  7.94
  7.64
  7.38
  7.14
  6.93
  6.73
  6.56
  6.40
  6.26
  6.14
  6.02
  5.92
  5.83
  5.75
  5.67
  5.60
  5.54
  5.49
Revenue, $m
  52
  60
  69
  78
  88
  98
  109
  120
  132
  145
  158
  172
  186
  201
  216
  232
  248
  266
  283
  302
  321
  342
  363
  384
  407
  431
  456
  481
  508
  537
  566
Variable operating expenses, $m
 
  87
  99
  112
  126
  141
  157
  173
  191
  209
  228
  247
  268
  289
  311
  334
  358
  382
  408
  435
  463
  492
  522
  554
  586
  620
  656
  693
  732
  773
  815
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  76
  87
  99
  112
  126
  141
  157
  173
  191
  209
  228
  247
  268
  289
  311
  334
  358
  382
  408
  435
  463
  492
  522
  554
  586
  620
  656
  693
  732
  773
  815
Operating income, $m
  -24
  -27
  -30
  -34
  -39
  -43
  -48
  -53
  -58
  -64
  -70
  -76
  -82
  -88
  -95
  -102
  -109
  -117
  -125
  -133
  -141
  -150
  -160
  -169
  -179
  -190
  -201
  -212
  -224
  -236
  -249
EBITDA, $m
  -22
  -24
  -28
  -31
  -35
  -40
  -44
  -49
  -53
  -59
  -64
  -69
  -75
  -81
  -87
  -94
  -100
  -107
  -114
  -122
  -130
  -138
  -146
  -155
  -164
  -174
  -184
  -194
  -205
  -217
  -229
Interest expense (income), $m
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
  6
  7
Earnings before tax, $m
  -24
  -27
  -30
  -35
  -39
  -44
  -49
  -54
  -59
  -65
  -71
  -77
  -83
  -90
  -97
  -104
  -112
  -120
  -128
  -136
  -145
  -154
  -164
  -174
  -184
  -195
  -206
  -218
  -230
  -243
  -256
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -24
  -27
  -30
  -35
  -39
  -44
  -49
  -54
  -59
  -65
  -71
  -77
  -83
  -90
  -97
  -104
  -112
  -120
  -128
  -136
  -145
  -154
  -164
  -174
  -184
  -195
  -206
  -218
  -230
  -243
  -256

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  28
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  66
  44
  50
  57
  64
  72
  80
  88
  97
  106
  116
  125
  136
  147
  158
  169
  182
  194
  207
  221
  235
  250
  265
  281
  298
  315
  333
  352
  372
  392
  414
Adjusted assets (=assets-cash), $m
  38
  44
  50
  57
  64
  72
  80
  88
  97
  106
  116
  125
  136
  147
  158
  169
  182
  194
  207
  221
  235
  250
  265
  281
  298
  315
  333
  352
  372
  392
  414
Revenue / Adjusted assets
  1.368
  1.364
  1.380
  1.368
  1.375
  1.361
  1.363
  1.364
  1.361
  1.368
  1.362
  1.376
  1.368
  1.367
  1.367
  1.373
  1.363
  1.371
  1.367
  1.367
  1.366
  1.368
  1.370
  1.367
  1.366
  1.368
  1.369
  1.366
  1.366
  1.370
  1.367
Average production assets, $m
  19
  21
  24
  28
  31
  35
  39
  43
  47
  52
  56
  61
  66
  71
  77
  83
  88
  95
  101
  108
  114
  122
  129
  137
  145
  153
  162
  171
  181
  191
  202
Working capital, $m
  25
  -3
  -4
  -5
  -5
  -6
  -6
  -7
  -8
  -8
  -9
  -10
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -18
  -19
  -20
  -21
  -22
  -24
  -25
  -26
  -28
  -29
  -31
  -33
Total debt, $m
  0
  3
  7
  10
  14
  19
  23
  28
  33
  38
  43
  48
  54
  60
  66
  73
  79
  86
  94
  101
  109
  117
  126
  134
  144
  153
  163
  174
  185
  196
  208
Total liabilities, $m
  21
  24
  28
  31
  35
  40
  44
  49
  54
  59
  64
  69
  75
  81
  87
  94
  100
  107
  115
  122
  130
  138
  147
  155
  165
  174
  184
  195
  206
  217
  229
Total equity, $m
  45
  20
  22
  25
  29
  32
  36
  39
  43
  47
  52
  56
  61
  66
  71
  76
  81
  87
  93
  99
  105
  112
  118
  126
  133
  141
  149
  157
  166
  175
  185
Total liabilities and equity, $m
  66
  44
  50
  56
  64
  72
  80
  88
  97
  106
  116
  125
  136
  147
  158
  170
  181
  194
  208
  221
  235
  250
  265
  281
  298
  315
  333
  352
  372
  392
  414
Debt-to-equity ratio
  0.000
  0.170
  0.300
  0.410
  0.500
  0.580
  0.650
  0.700
  0.750
  0.790
  0.830
  0.860
  0.890
  0.920
  0.940
  0.960
  0.980
  1.000
  1.010
  1.020
  1.040
  1.050
  1.060
  1.070
  1.080
  1.090
  1.100
  1.100
  1.110
  1.120
  1.120
Adjusted equity ratio
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447
  0.447

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -24
  -27
  -30
  -35
  -39
  -44
  -49
  -54
  -59
  -65
  -71
  -77
  -83
  -90
  -97
  -104
  -112
  -120
  -128
  -136
  -145
  -154
  -164
  -174
  -184
  -195
  -206
  -218
  -230
  -243
  -256
Depreciation, amort., depletion, $m
  2
  2
  3
  3
  3
  4
  4
  4
  5
  5
  6
  6
  7
  7
  8
  8
  9
  10
  10
  11
  12
  12
  13
  14
  15
  16
  17
  17
  18
  19
  21
Funds from operations, $m
  -11
  -24
  -28
  -32
  -36
  -40
  -45
  -49
  -54
  -60
  -65
  -71
  -77
  -83
  -89
  -96
  -103
  -110
  -117
  -125
  -133
  -142
  -150
  -160
  -169
  -179
  -189
  -200
  -211
  -223
  -235
Change in working capital, $m
  4
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
Cash from operations, $m
  -15
  -24
  -27
  -31
  -35
  -39
  -44
  -49
  -54
  -59
  -64
  -70
  -76
  -82
  -88
  -95
  -102
  -109
  -116
  -124
  -132
  -141
  -149
  -158
  -168
  -178
  -188
  -199
  -210
  -221
  -234
Maintenance CAPEX, $m
  0
  -2
  -2
  -2
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -12
  -12
  -13
  -14
  -15
  -16
  -17
  -17
  -18
  -19
New CAPEX, $m
  -5
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
  -10
  -10
Cash from investing activities, $m
  10
  -5
  -5
  -5
  -6
  -7
  -8
  -8
  -8
  -9
  -10
  -11
  -11
  -12
  -12
  -14
  -14
  -15
  -16
  -17
  -18
  -19
  -19
  -21
  -22
  -23
  -25
  -26
  -27
  -28
  -29
Free cash flow, $m
  -5
  -29
  -33
  -37
  -41
  -46
  -51
  -57
  -62
  -68
  -74
  -81
  -87
  -94
  -101
  -109
  -116
  -124
  -132
  -141
  -150
  -159
  -169
  -179
  -190
  -201
  -212
  -224
  -237
  -250
  -264
Issuance/(repayment) of debt, $m
  0
  3
  3
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  8
  9
  9
  10
  10
  10
  11
  11
  12
Issuance/(repurchase) of shares, $m
  0
  29
  33
  38
  42
  47
  52
  58
  63
  69
  75
  81
  88
  95
  102
  110
  117
  125
  134
  142
  151
  161
  170
  181
  191
  202
  214
  226
  239
  252
  266
Cash from financing (excl. dividends), $m  
  0
  32
  36
  42
  46
  51
  56
  63
  68
  74
  80
  87
  94
  101
  108
  116
  124
  132
  141
  150
  159
  169
  178
  190
  200
  212
  224
  236
  250
  263
  278
Total cash flow (excl. dividends), $m
  -5
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
Retained Cash Flow (-), $m
  22
  -29
  -33
  -38
  -42
  -47
  -52
  -58
  -63
  -69
  -75
  -81
  -88
  -95
  -102
  -110
  -117
  -125
  -134
  -142
  -151
  -161
  -170
  -181
  -191
  -202
  -214
  -226
  -239
  -252
  -266
Prev. year cash balance distribution, $m
 
  28
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  3
  -29
  -33
  -38
  -42
  -47
  -52
  -58
  -63
  -69
  -75
  -81
  -88
  -95
  -102
  -109
  -117
  -125
  -134
  -142
  -151
  -161
  -170
  -181
  -191
  -202
  -214
  -226
  -239
  -252
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  3
  -27
  -29
  -31
  -33
  -34
  -35
  -36
  -36
  -36
  -36
  -35
  -33
  -32
  -30
  -28
  -26
  -23
  -21
  -18
  -16
  -13
  -11
  -9
  -7
  -6
  -5
  -3
  -3
  -2
Current shareholders' claim on cash, %
  100
  82.3
  67.8
  56.0
  46.3
  38.3
  31.8
  26.4
  22.0
  18.3
  15.2
  12.7
  10.6
  8.9
  7.4
  6.2
  5.2
  4.3
  3.6
  3.0
  2.6
  2.1
  1.8
  1.5
  1.3
  1.1
  0.9
  0.7
  0.6
  0.5
  0.4

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

FINANCIAL RATIOS  of  Antares Pharma (ATRS)

Valuation Ratios
P/E Ratio -14.5
Price to Sales 6.7
Price to Book 7.8
Price to Tangible Book
Price to Cash Flow -23.3
Price to Free Cash Flow -17.5
Growth Rates
Sales Growth Rate 13%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -28.6%
Cap. Spend. - 3 Yr. Gr. Rate 10.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0.1
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -31.8%
Ret/ On Assets - 3 Yr. Avg. -34.5%
Return On Total Capital -42.9%
Ret/ On T. Cap. - 3 Yr. Avg. -48.1%
Return On Equity -42.9%
Return On Equity - 3 Yr. Avg. -48.1%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 44.2%
Gross Margin - 3 Yr. Avg. 52.1%
EBITDA Margin -42.3%
EBITDA Margin - 3 Yr. Avg. -69.1%
Operating Margin -46.2%
Oper. Margin - 3 Yr. Avg. -73.1%
Pre-Tax Margin -46.2%
Pre-Tax Margin - 3 Yr. Avg. -73.1%
Net Profit Margin -46.2%
Net Profit Margin - 3 Yr. Avg. -73.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. -1.7%
Payout Ratio 0%

ATRS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ATRS stock intrinsic value calculation we used $52 million for the last fiscal year's total revenue generated by Antares Pharma. The default revenue input number comes from 2016 income statement of Antares Pharma. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ATRS stock valuation model: a) initial revenue growth rate of 15.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ATRS is calculated based on our internal credit rating of Antares Pharma, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Antares Pharma.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ATRS stock the variable cost ratio is equal to 144.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ATRS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Antares Pharma.

Corporate tax rate of 27% is the nominal tax rate for Antares Pharma. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ATRS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ATRS are equal to 35.6%.

Life of production assets of 9.8 years is the average useful life of capital assets used in Antares Pharma operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ATRS is equal to -5.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $45 million for Antares Pharma - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 158.764 million for Antares Pharma is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Antares Pharma at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
TEVA Teva Pharmaceu 20.70 42.97  str.buy
ANIP ANI Pharmaceut 69.94 65.88  hold
CAH Cardinal Healt 71.91 123.25  str.buy
BDX Becton Dickins 234.51 68.37  str.sell
PFE Pfizer 36.94 28.29  sell
WST West Pharmaceu 100.61 49.05  str.sell
LLY Eli Lilly 85.49 111.38  buy

COMPANY NEWS

▶ Antares Pharma Provides XYOSTED Regulatory Update   [Jan-16-18 07:00AM  GlobeNewswire]
▶ Antares Pharma Provides XYOSTED Regulatory Update   [Dec-21-17 04:01PM  GlobeNewswire]
▶ Antares Pharma reports 3Q loss   [07:19AM  Associated Press]
Financial statements of ATRS
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.